

Area Drugs and Therapeutics Committee Meeting Minutes

Wednesday 21st February 2024 10-12:30

Microsoft Teams Meeting

Present:	Mehrdad Malekian (Chair) Victoria Gemmell Stephanie Dundas Colin Angus Tyra Smyth David Semple Kirsty MacFarlane Christine Carswell Linda Johnstone	Christine Gilmour Emma Harris Gail Richardson Christine Gilmour Alistair Brown Rebecca Ritchie (until item 8b) Isabel Howat (Item 8f) Jacqueline MacDonald (Item 8d)
-----------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

1. Apologies:	Mark Kirk, Kelly Baillie
----------------------	--------------------------

2. Declaration of Interest	Isabel Howat declared receipt of previous educational grants from Novo Nordisk
-----------------------------------	--------------------------------------------------------------------------------

--	--	--

Item	Notes	Action
------	-------	--------

3	<u>Minutes/Actions from the last meeting</u> These were not agreed-2 points to amend. To return next month.	VG
----------	-----------------------------------------------------------------------------------------------------------------------	----

4	<u>Matters Arising</u>	
a)	Ogluo Updated guidance after comments in January was discussed. The group requested further clarification around patient review by paediatric diabetic services before transfer to adult services. This was approved pending the change.	MM
b)	Orbital Cellulitis Guideline NHSL This was approved	
c)	Management of Malignant Hypercalcaemia Carried over to next month	

5	<u>SMC Advice-CONFIDENTIAL</u> Please all see attached Advice from the Scottish Medicines Consortium which will be published on the SMC website after 10.00 am on Monday 11 March 2024. <u>Full Submissions</u>	
	<ul style="list-style-type: none"> • talazoparib (Talzenna) Pfizer Limited SMC2607 Accepted with PAS Await advice from WoSCAN • axicabtagene ciloleucel dispersion for infusion (Yescarta) Kite, a Gilead company SMC2628 Not Recommended This was noted • olaparib (Lynparza) AstraZeneca UK Ltd SMC2617 Accepted with PAS Await advice from WoSCAN • ivosidenib (Tibsovo) Servier Laboratories SMC2615 Accepted with PAS Await advice from WoSCAN 	

	<p><u>Abbreviated Submission</u></p> <ul style="list-style-type: none"> • foslevodopa-foscarbidopa (Produodopa) AbbVie Ltd SMC2574 Accepted Restricted with PAS Refer to Parkinson's service <p><u>Non Submissions</u></p> <ul style="list-style-type: none"> • pitolisant film-coated tablets (Wakix) Bioprojet UK Limited SMC2662 • satralizumab solution for injection in pre-filled syringe (Enspryng) Roche Products Ltd SMC2663 <p>These were noted</p> <p><u>FOR INFORMATION</u></p> <p><i>Note: Budget Impact templates will be sent to NHS Board contacts and Directors of Pharmacy under separate cover.</i></p> <p><u>Paediatric License Extensions</u></p> <p>FOR NOTING</p>	
6.	<p><u>SMC follow up</u> This was discussed.</p>	
7.	<p><u>Lanarkshire Formulary</u></p> <p>These were agreed</p>	
8.	<p><u>Clinical Protocols</u></p> <p>(a) Off-Label Prescribing (Use of Medicines Outside of their UK Marketing Authorisation in Palliative Medicine-Prescribing for Off-Label Indications or Unlicensed Medicines) This was discussed. Links to new NHSL Unlicensed Policy will be added when this is agreed and online. There was discussion around the need for a specific unlicensed/off label palliative care document. The group felt the medicines list was particularly helpful, however some other sections could be streamlined. KMAC and LJ will collaborate. It was also felt that clarity around who will monitor patients would be helpful. Document to return for final approval.</p> <p>(b) Unlicensed Medicines KMAC gave a summary. This is an overhaul of the current unlicensed medicine process and includes an update of current forms. GR noted the new forms would need to include biologic/live products. There was also discussion on when completion of a form for off-label use of a medicine would be required, and the need and merits of this. It was agreed that the policy should be shared widely. A question was asked about the PIL. This will follow Board process for PIL's. To return for final approval</p>	<p>LJ/ KMAC</p> <p>KMAC</p>

	<p>(c) SGLT2i for Treatment of Chronic Kidney Disease The committee felt it would be helpful to clarify if the author collaborated with other specialities. SGLT2 CKD NHSL Guideline-Expand abbreviations. Protocols approved with no changes. Clinical Guideline to return for final approval.</p> <p>(d) Treatment of Nicotine Addiction JM gave a summary. This was noted, however it was agreed that in the future this could be agreed through operational groups.</p> <p>(e) Ryego SMC Restriction to be included in protocol. DXA scanning arrangements to be clarified. Request for assurance from author that patients will be seen in clinic as per protocol at stated intervals Document to return for final approval</p> <p>(f) Weight Management Wegovy® (Semaglutide) IH gave a summary of the guideline. This will be provided through Tier 3 Weight Management Services. The guideline was agreed in principle, with supply route to be confirmed in due course. To be shared with both Medicine Management Boards.</p> <p>(g) Midazolam (Epistatus) for Treatment of Seizures in Paediatric Patients Small typo page 2 “in epi- “instead of “of Epi- “. Accepted pending change noted above.</p> <p>(h) NIV Withdrawal Guideline This was discussed. The committee felt that it would be helpful to clarify target audience, and confirm engagement with other specialities and sites. Latin references should be in English. Table on pg 2 is colourful, but clarity on how they relate would be helpful. References to syringe driver treatment needs strengthened with doses added.</p> <p>(i) JIC Guidance This an update to previous guidance. This was approved.</p>	
9.	<p><u>ADTC New Medicines Decisions</u></p> <p>This was agreed</p>	
10.	<p><u>Unlicensed Medicines</u></p> <p>This was discussed. There are problems with the supply of salbutamol nebulas. There is high usage of this across all Acute sites and Primary Care so use of an unlicensed version from USA was proposed. This was agreed.</p>	
11.	<p><u>Medication and Clinical risk in Lanarkshire</u></p> <p>https://www.gov.uk/drug-safety-update</p>	

	nil	
12.	<u>Regional Cancer Advisory Network</u> nil	
13.	<u>Patient Safety Alerts</u> nil	
14.	<u>Lay member related items</u> CA asked a question about financial governance of medicine spend. CG explained that ADTC not have a financial remit but responsibility for financial oversight lies with the respective Medicines Management Boards	
15.	<u>Correspondence</u> (a) <u>ADTC Collaborative</u> (i) Sodium Valproate Learning Network-update VG gave an update on work that is underway in response to the NPS Alert for valproate products issued Jan 2024. (ii) Medicines Procurement Newsletter This was noted	
15.	<u>Pharmacy & NMAHP Prescribing Governance</u> nil	
16.	<u>AOCB</u> (a) KMAC presented new PGD Guidance. This clarifies the process and updates current templates. It includes vaccination and Pharmacy First PGD's, as well as those for use in Acute and Primary Care settings. The committee agreed that a database is necessary to capture all PGD's in use and track expiry. A standard template for Acute and Primary Care/Community will be circulated for electronic agreement. It was also suggested to update signatory names to titles. The policy was approved.	KMAC
17.	<u>Date of next meeting</u> Wednesday 20 th March 2024 10am-12:30pm MS TEAMS	